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ABSTRACT: The recent crystal structures of CC chemokine
receptors 2 and 9 (CCR2 and CCR9) have provided
structural evidence for an allosteric, intracellular binding
site. The high conservation of residues involved in this site
suggests its presence in most chemokine receptors, including
the close homologue CCR1. By using [3H]CCR2-RA-[R], a
high-aﬃnity, CCR2 intracellular ligand, we report an intra-
cellular binding site in CCR1, where this radioligand also
binds with high aﬃnity. In addition, we report the synthesis and biological characterization of a series of pyrrolone derivatives
for CCR1 and CCR2, which allowed us to identify several high-aﬃnity intracellular ligands, including selective and potential
multitarget antagonists. Evaluation of selected compounds in a functional [35S]GTPγS assay revealed that they act as inverse
agonists in CCR1, providing a new manner of pharmacological modulation. Thus, this intracellular binding site enables the
design of selective and multitarget inhibitors as a novel therapeutic approach.
■ INTRODUCTION
Chemokines are chemotactic cytokines that control the
migration and positioning of immune cells during physiological
and pathological conditions by interacting with more than 20
diﬀerent chemokine receptors.1 Chemokine receptors mainly
belong to the class A of G protein-coupled receptors (GPCRs)
and can be divided into four diﬀerent subtypes, namely C, CC,
CXC, and CX3C, according to the pattern of speciﬁc cysteine
residues in their major endogenous chemokines.2 To exert
their function, chemokines bind at the extracellular side of
their receptors in a binding mechanism involving the N-
terminal domain, extracellular loops, and the upper half of the
transmembrane bundle.3,4 After activation, most chemokine
receptors signal through heterotrimeric G proteins, mainly Gi/o
class, and β-arrestins.2 CC chemokine receptors 1 (CCR1) and
2 (CCR2) are two of the 10 members of the CC subtype of
chemokine receptors. CCR1 and CCR2 are expressed in a
variety of immune cells, such as monocytes, dendritic cells, and
T helper type-1 (TH1) cells, from where they regulate diverse
inﬂammatory and homeostatic functions.5 Multiple chemo-
kines activate these two receptors, including CCL3, CCL5, and
CCL8 in the case of CCR1, and CCL2, CCL7, and CCL8 in
the case of CCR2.2
Dysregulation of CCR1, CCR2, and their ligands has been
linked to several inﬂammatory and immune diseases,6,7 which
has resulted in many drug discovery eﬀorts to develop small
molecules that target these receptors.8,9 Several lines of
evidence support a role for both CCR1 and CCR2 in the
pathogenesis of diseases such as rheumatoid arthritis (RA) and
multiple sclerosis (MS): increased expression of both receptors
and their ligands in disease models and patients,10,11 protective
eﬀect of genetic knockout of CCR1 or CCR2 in disease
models,12,13 and positive preclinical studies with chemokine-
neutralizing monoclonal antibodies or small-molecule inhib-
itors of CCR1 or CCR2.14−16 Yet, only few clinical studies
have shown promising results,17,18 while most of the drugs
developed so far have failed in clinical trials due to lack of
eﬃcacy.8,9 In this regard, the development of multitarget drugs
has been proposed as a strategy to overcome the lack of
eﬃcacy. Multitarget drugs are designed to speciﬁcally act on
more than one drug target, which might be necessary in highly
heterogeneous diseases, such as RA and MS, where more than
one chemokine receptor is involved.19 The design of dual
antagonists has been previously undertaken for CCR1/
CCR3,20 CCR2/CCR5,21 CCR5/CXCR4,22 and CXCR1/
CXCR2;23 however, no CCR1/CCR2 dual antagonists have so
far been reported.
Recently, the crystal structures of CCR224 and CCR925 have
revealed a novel allosteric binding site for small molecules in
chemokine receptors. Both CCR2-RA-[R] in CCR2 and
vercirnon in CCR9 bind in a pocket located in the intracellular
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surface of the receptors, partially overlapping with the binding
site for G proteins and β-arrestins.24,25 These intracellular
ligands can inhibit the receptors in a noncompetitive and
insurmountable manner with regard to chemokine binding, as
demonstrated previously in CCR2.26 This might result in
higher eﬃcacy even in the presence of a high local
concentration of chemokines during a disease state. Together
with the potential advantages of allosteric modulators of
chemokine receptors, this intracellular binding site seems to be
quite conserved among chemokine receptors, which suggests
the presence of homologous pockets in other receptors such as
CCR1.27 This conservation might provide an opportunity for
the design of both selective and dual-targeting inhibitors of
CCR1 and CCR2 as a novel approach to treat inﬂammatory
and immune diseases.
For CCR2, several compounds belonging to diﬀerent
scaﬀolds have already been reported to bind to this
intracellular binding site, including pyrrolone derivatives such
as CCR2-RA-[R], sulfonamide derivatives, and 2-mercapto
imidazoles.26,28 When tested for selectivity, some of these
compounds also displayed a moderate activity on CCR1,29−31
suggesting that they might also bind to CCR1. Thus, we
selected the pyrrolone scaﬀold to explore a potential
intracellular binding site in CCR1. In our current study, we
report the synthesis and the biological evaluation of novel and
previously patented pyrrolone derivatives32,33 at both CCR1
and CCR2 in order to determine their selectivity and
structure−aﬃnity relationships (SAR) for both receptors.
Finally, compounds were tested in a [35S]GTPγS binding
assay in order to determine their functional eﬀects in CCR1
and CCR2. Overall, our results provide evidence that CCR1
can also be targeted with intracellular allosteric modulators and
that this binding site can be used for the design of multitarget
compounds.
■ RESULTS AND DISCUSSION
Synthesis of Pyrrolone Derivatives. The racemic
pyrrolones (6−24, 26−46) depicted in Scheme 1 were
synthesized via a one-pot three-component condensation
reaction, starting from the commercially available substituted
aldehydes 1a−l, anilines 2a−q, and ethyl 2,4-dioxo-butanoates
3a−i in acetic acid33 (6−23, 26−46) or THF29 (24). The
ethyl 2,4-dioxo-butanoates (3b−d,f,i), which were not
commercially available, were prepared by a Claisen con-
densation starting from the methyl ketones (4b−d,f,i) and
diethyl oxalate 5.34 Pyrrolone 25 was prepared via a
transesteriﬁcation of 24 by the use of p-toluenesulfonic acid
in 2-propanol.
Characterization of [3H]-CCR2-RA-[R] Binding on
CCR1 and CCR2. [3H]-CCR2-RA-[R] is the (R)-isomer of
[3H]-CCR2-RA, a high-aﬃnity radioligand previously charac-
terized in our group for CCR2.26 To avoid a possible eﬀect of
the lower-aﬃnity isomer, we used the tritium-labeled (R)-
isomer in the present study. As expected, [3H]-CCR2-RA-[R]
binds with high aﬃnity to osteosarcoma (U2OS) cells stably
expressing CCR2b (U2OS-CCR2) as shown by saturation
experiments (KD of 6.3 nM and Bmax of 2.6 pmol/mg,
Supporting Information, Figure S1 and Table S1). Kinetic
characterization showed that [3H]-CCR2-RA-[R] associates
and dissociates in a biphasic manner (Supporting Information,
Table S1), consistent with the previously reported [3H]-
CCR2-RA kinetics.26 We had reported that [3H]-CCR2-RA
binds with low aﬃnity to CCR5 (KD of 100 nM),
28 suggesting
that CCR2-RA-[R] is a nonselective antagonist that can bind
several chemokine receptors. In this regard, CCR1 is a close
homologue of CCR2, with 61% amino acid similarity and 47%
identity; furthermore, this amino acid similarity is >90% when
only considering the amino acid residues involved in the
intracellular binding site of CCR2-RA-[R] in CCR224
(Supporting Information, Figure S2). This prompted us to
investigate the binding of [3H]-CCR2-RA-[R] in membrane
preparations from U2OS cells stably expressing CCR1 (U2OS-
Scheme 1. Synthesis Route of Pyrrolones 6−48, with Diﬀerent R1, R2, and R3 Substituentsa
aReagents and conditions: (a) acetic acid, reﬂux for 2−4 h or THF, rt, overnight; (b) Na, EtOH, 0−20 °C, overnight; (c) p-toluenesulfonic acid, 2-
propanol, reﬂux, 48 h.
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CCR1). [3H]-CCR2-RA-[R] homologous displacement assays
on U2OS-CCR1 yielded a KD of 13.5 nM and a Bmax of 6.1
pmol/mg (Figure 1a, Supporting Information, Table S1),
suggesting the presence of an intracellular site in CCR1 and
making it a suitable tool to study such binding pocket. Binding
of [3H]-CCR2-RA-[R] to U2OS-CCR1 was also assessed in
Figure 1. (a) Homologous displacement curves of 3, 6, and 12 nM [3H]-CCR2-RA-[R] speciﬁc binding by increasing concentrations of CCR2-RA-
[R] in U2OS-CCR1 at 25 °C. (b) Displacement curves of 6 nM [3H]-CCR2-RA-[R] speciﬁc binding by increasing concentrations of SD-24, JNJ-
27141491, and BX471 in U2OS-CCR1 at 25 °C. BX471 signiﬁcantly enhanced the binding of [3H]-CCR2-RA-[R] up to 120%. Statistical
signiﬁcance between binding in absence (100%) and presence of 10 μM BX471 (116 ± 2%) was determined using an unpaired, two-tailed
Student’s t-test with Welch’s correction. (c,d) Displacement curves of 6 nM [3H]-CCR2-RA-[R] speciﬁc binding by compounds 39, 41, 43, and 45
(b) in U2OS-CCR1 or (c) in U2OS-CCR2 at 25 °C. In the case of U2OS-CCR2, compound 45 did not displace more than 50% of [3H]-CCR2-
RA-[R], thus only single-point data at 1 μM is shown. The dashed blue line corresponds to the nonlinear regression ﬁt for compound 45 by
GraphPad Prism 7.0. Data shown are mean ± SEM of at least three experiments performed in duplicate.
Figure 2. Proposed binding mode of compound CCR2-RA-[R] in the homology models of CCR1 and CCR2, based on the crystal structure of
CCR2 (PDB 5T1A).24 For CCR1, representative residues are shown as green “sticks” and for CCR2 as orange “sticks”. In all cases, oxygen and
nitrogen atoms are represented in red and blue, respectively, and hydrogen bonds with dashed yellow lines. Residues are numbered based on the
corresponding residue numbers and with structure-based Ballesteros−Weinstein numbers in superscript.37
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kinetic experiments at 25 °C. These experiments showed that
[3H]-CCR2-RA-[R] associates and dissociates in a biphasic
manner, similar to our ﬁndings in CCR2, but the association
and dissociation rates were signiﬁcantly higher in CCR1 than
in CCR2 (Supporting Information, Figure S1 and Table S1).
Overall, these ﬁndings allowed us to set up a [3H]-CCR2-
RA-[R] competitive displacement assay on both U2OS-CCR1
and U2OS-CCR2 to determine the binding aﬃnity (Ki) of
unlabeled compounds. Using this assay, we ﬁrst determined
the ability of known ligands to displace this radioligand from
CCR1, i.e., the CCR2 intracellular ligands SD-24 and JNJ-
2714149126,28 and the CCR1 orthosteric antagonist BX47135
(Figure 1b). SD-24 and JNJ-27141491 fully displaced [3H]-
CCR2-RA-[R] from CCR1 in a concentration-dependent
manner, indicating that these compounds bind at the same
binding site as CCR2-RA-[R]. SD-24 displaced the radioligand
with a pKi of 7.45 ± 0.05 (Ki = 36 nM), while JNJ-27141491
displaced [3H]-CCR2-RA-[R] with a pKi of 6.9 ± 0.06 (Ki =
138 nM), consistent with previously reported activities in
CCR1.30,31 To rule out that these compounds bind at the
orthosteric binding site of CCR1, we also investigated the
eﬀect of BX471 in [3H]-CCR2-RA-[R] binding. As expected,
BX471 was not able to displace the radioligand (Figure 1b); on
the contrary, BX471 signiﬁcantly enhanced the binding of
[3H]-CCR2-RA-[R] by approximately 20% (116 ± 2% in the
presence of 10 μM BX471), in a similar manner as previously
reported with CCR2 orthosteric antagonists.24,26 This
allosteric enhancement is consistent with two diﬀerent binding
sites in CCR1: the orthosteric binding site where BX471 binds
and an intracellular pocket for CCR2-RA-[R], SD-24, and JNJ-
27141491.
This [3H]-CCR2-RA-[R] assay was also used to determine
the aﬃnity of the synthesized pyrrolone derivatives. All
pyrrolone derivatives 6−46 were ﬁrst tested at a single
concentration of 1 μM in both U2OS-CCR1 and U2OS-CCR2
(Tables 1−3). Compounds which displaced more than 50% of
[3H]-CCR2-RA-[R] binding were further evaluated in this
assay using at least six diﬀerent concentrations of unlabeled
compound in order to determine their binding aﬃnity for the
corresponding receptor subtypes (Figure 1c,d and Tables
1−3). Finally, we selected four compounds (39, 41, 43 and
45) to be tested in a functional [35S]GTPγS binding assay
(Figure 3). The potency (pIC50) of these compounds was
determined in the presence of an EC80 concentration of CCL3
(8 nM) or CCL2 (20 nM) in U2OS-CCR1 or U2OS-CCR2
membranes, respectively.
Docking of CCR2-RA-[R] in CCR1 and CCR2. To better
understand the binding mode of CCR2-RA-[R] in both human
CCR1 and CCR2b, we docked this compound into models of
both receptors (Figure 2). In the case of CCR2, homology
modeling was used to model the CCR2 residues between
Ser2265x62 and Lys2406x32, which correspond to the M2
muscarinic acetylcholine receptor sequence in the CCR2b
crystal structure (PDB 5T1A).24 These residues were modeled
because this region is in close proximity to the CCR2-RA-[R]
binding site. As expected from the sequence alignment
(Supporting Information, Figure S2), CCR2-RA-[R] was
predicted to bind to CCR1 in an overlapping binding site as
Table 1. Binding Aﬃnities of Compounds 6−26 on Human CCR1 and Human CCR2
pKi ± SEM (Ki, nM)
a or displacement at 1 μM (%)b
compd R1 R3 CCR1 CCR2
6 c-hexyl Me 7.26 ± 0.04 (56) 7.10 ± 0.03 (81)
7 c-heptyl Me 7.26 ± 0.03 (56) 7.02 ± 0.06 (96)
8 c-octyl Me 7.24 ± 0.01 (57) 6.79 ± 0.09 (170)
9 Ph Me 6.79 ± 0.04 (162) 39% (38, 40)
10 4-Me Ph Me 6.71 ± 0.06 (198) 36% (42, 31)
11 4-OMe Ph Me 6.27 ± 0.01 (541) 5% (5, 5)
12 4-Cl Ph Me 7.17 ± 0.01 (67) 6.70 ± 0.08 (207)
13 4-Br Ph Me 7.07 ± 0.07 (87) 6.67 ± 0.03 (214)
14 3-Me Ph Me 47% (51, 44) 11% (14, 8)
15 3-OMe Ph Me 28% (34, 22) 0% (3, −3)
16 3-Cl Ph Me 6.70 ± 0.01 (198) 19% (25, 14)
17 3-Br Ph Me 6.74 ± 0.02 (181) 19% (20, 18)
18 c-hexyl Et 7.52 ± 0.01 (30) 6.99 ± 0.06 (104)
19 c-hexyl Pr 7.54 ± 0.04 (29) 6.86 ± 0.10 (144)
20 c-hexyl Bu 7.50 ± 0.004 (31) 6.81 ± 0.05 (158)
21 c-hexyl I-Pr 7.39 ± 0.06 (42) 6.50 ± 0.05 (316)
22 c-hexyl c-Pr 7.74 ± 0.08 (19) 6.80 ± 0.05 (160)
23 c-hexyl t-Bu 7.66 ± 0.05 (22) 6.81 ± 0.07 (158)
24 c-hexyl OEt 6.70 ± 0.01 (200) 31% (36, 26)
25 c-hexyl OiPr 36% (45, 26) 6% (10, 1)
26 c-hexyl −Ph 7.11 ± 0.01 (77) 37% (45, 30)
apKi and Ki (nM) values obtained from [
3H]-CCR2-RA-[R] binding assays on U2OS membranes stably expressing human CCR1 or human CCR2.
Values are means ± standard error of the mean (SEM) of at least three independent experiments performed in duplicate. bPercent of [3H]-CCR2-
RA-[R] displacement by 1 μM compound. Values represent the mean of two independent experiments performed in duplicate.
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the one reported in the crystal structure of CCR2,24 in a
solvent-exposed intracellular pocket found between the
intracellular ends of transmembrane segments 1−3, 6, 7, and
helix 8 (Figure 2). The vinylogous carboxylic acid functionality
makes similar interactions in CCR1 as in CCR2: the hydroxyl
and the two carbonyl groups are involved in hydrogen-bond
interactions with the side chain of Arg1313x50, and the
backbone of Arg3078x49 and Phe3088x50 (Figure 2). A similar
hydrophobic subpocket is also observed around the cyclohexyl
moiety, which interacts with Ala6x33, Val/Leu6x36, Ile6x37, and
Ile6x40. Interestingly, Val2446x36 in CCR2 is replaced by the
bigger Leu2406x36 in CCR1, which pushes the ligand down
against Arg1313x50, resulting in a slightly diﬀerent binding
orientation of CCR2-RA-[R] in this receptor (Figure 2). In
addition, the exchange of Lys3118x49 in CCR2 by Arg3078x49 in
CCR1 might also contribute to the stabilization of this slightly
altered binding pose. This diﬀerence in orientation could result
in CCR1 selectivity, as this orientation seems to open up the
subpockets in the proximity of the cyclohexyl and the acetyl
group of CCR2-RA-[R] in CCR1, allowing the introduction of
bigger and more lipophilic substituents at these positions.
Structure−Aﬃnity Relationships (SAR). Modiﬁcations
Replacing the Cyclohexyl Group (R1, Table 1). Several
pyrrolone derivatives have been previously evaluated at
CCR2,29,32,33,36 resulting in the identiﬁcation of CCR2-RA-
[R] as a hit compound for further development,29 but
characterization of these compounds in CCR1 is mostly
missing. Compound 6, previously reported and characterized
in CCR2 by Zou et al. (2007),36 was selected as our starting
point for the analysis of SAR in both CCR1 and CCR2. In our
assay, compound 6 showed an aﬃnity of 81 nM for CCR2 and
a slightly higher aﬃnity of 56 nM for CCR1 (Table 1). To
note, the binding aﬃnities reported previously for these
pyrrolone derivatives were obtained with a 125I-CCL2 binding
assay,29,36 resulting in lower aﬃnities compared with our [3H]-
CCR2-RA-[R] binding assay, as previously observed in our
group.26 For our SAR study, we ﬁrst examined diﬀerent C5
substituents of the pyrrolone core (R1), as shown in Table 1.
In line with previous studies,29 we found that increasing the
size of the cycloalkyl group from cyclohexyl (6) to cycloheptyl
(7) or cyclooctyl (8) resulted in a decrease in binding aﬃnity
for CCR2; however, the aﬃnity for CCR1 was retained,
indicating that bulkier groups are better tolerated in CCR1
than in CCR2 and providing an avenue for selectivity on
CCR1 over CCR2. Previous studies showed that decreasing
the size of the cycloalkyl group was also detrimental for
CCR2,29 so we decided not to explore smaller ring sizes.
Substitution of the cycloalkyl group by a phenyl group (9)
led to a great loss of CCR2 aﬃnity (39% displacement at 1
μM), consistent with previously reported values showing a
decreased aﬃnity for an almost similar pair of compounds.36
Yet this substitution only led to a 3-fold decrease in CCR1
aﬃnity (Ki of 162 nM), thus showing much higher selectivity
for CCR1. Next, we explored the eﬀect of N-aryl modiﬁcations
in both aﬃnity and selectivity (compounds 10−17),
speciﬁcally the eﬀect of para and meta substituents. In general,
N-aryl groups on the R1 position resulted in increased
selectivity toward CCR1, as most compounds did not displace
more than 36% [3H]-CCR2-RA-[R] binding in CCR2 at a
concentration of 1 μM. Only compounds 12 and 13, with
halogen substitutions in para position (Cl and Br, respec-
tively), regained CCR2 aﬃnity (12, 207 nM; 13, 214 nM).
Furthermore, para-substituted derivatives displayed signiﬁ-
cantly higher aﬃnities compared with their meta-substituted
analogues.
In the case of CCR1, introduction of a para-methyl moiety
(10) resulted in a slight decrease in aﬃnity compared with the
unsubstituted 9; in contrast, the meta-substituted analogue
(14) showed less than 50% displacement at 1 μM.
Introduction of an electron-donating substituent (methoxy,
11 and 15) was not well tolerated in any position, as it led to
an approximately 3-fold decrease in aﬃnity when placed in
para position (11, 541 nM) and a near complete loss of aﬃnity
when placed in meta position (15, 28% displacement at 1 μM).
Halogen substituents in para position were also more favored
in the case of CCR1, yielding higher aﬃnities compared with
the unsubstituted 9 and regardless of the halogen used (67 nM
for R1 = 4-Cl phenyl (12), p < 0.0001 to 9; 87 nM for R1 = 4-
Br phenyl (13); p = 0.0002 to 9). However, selectivity for
CCR1 was notably reduced considering that these compounds
displayed binding aﬃnities of around 200 nM in CCR2.
Although moving the halogens to the meta position (16 and
17) decreased the aﬃnities more than 2-fold compared with
their para analogues, selectivity for CCR1 was restored as these
compounds showed less than 20% displacement of [3H]-
CCR2-RA-[R] binding in CCR2. Together, the results for
compounds 6−17 indicate that in CCR1 aliphatic groups yield
higher aﬃnities, while aromatic groups yield lower aﬃnities but
improved selectivity over CCR2.
Modiﬁcations to the Acetyl Group (R3, Table 1). Previous
modiﬁcations to the vinylogous carboxylic acid functionality in
CCR2 showed detrimental eﬀects in binding aﬃnity.29,36
Indeed, mutagenesis and structural studies have shown crucial
interactions of the hydroxyl and the two carbonyl groups with
Glu3108x48, Lys3118x49, and Phe3128x50 (residues according to
structure-based Ballesteros−Weinstein numbering37) in
CCR2.24,28 Sequence alignment of CCR1 and CCR2
(Supporting Information, Figure S2) and our docking study
(Figure 2) suggest similar interactions in CCR1, as only
position 8.49 diﬀers (arginine in CCR1 and lysine in CCR2).
Therefore, we decided to keep the vinylogous carboxylic acid
moiety and explore diﬀerent modiﬁcations to the acetyl group
at the R3 position (Table 1). A gradual increase in the length of
the alkyl chain from a methyl group (6) to a butyl group (18−
20) resulted in a ∼2-fold increase in CCR1 aﬃnity (30 nM for
R3 = ethyl (18), p = 0.0004 against 6; 29 nM for R3 = propyl
(19), p = 0.0002 against 6; and 31 nM for R3 = butyl (20), p =
0.0010 against 6). In contrast, for CCR2, we observed a similar
or a slight decrease in aﬃnity. Introduction of a bulkier
isopropyl group led to a decrease in aﬃnity in both receptors,
with a more drastic eﬀect in CCR2 aﬃnity. Replacing the
isopropyl group with cyclopropyl (22) or tert-butyl (23)
restored the aﬃnity in CCR2 to values similar to compound 20
(22, 160 nM; 23, 158 nM); in CCR1, these modiﬁcations
further improved the binding aﬃnity to approximately 20 nM,
yielding compounds with the highest aﬃnity and selectivity
observed in these series of R1 and R3 modiﬁcations (22, 19
nM; 23, 22 nM). These results suggest a larger hydrophobic
subpocket in CCR1, able to accommodate larger and branched
alkyl chains.
We also explored the eﬀect of adding heteroatoms (oxygen
in this case) between the carbonyl and an ethyl or isopropyl
group (24 and 25, respectively). Overall, this led to a drastic
drop in aﬃnity for both receptors. This detrimental eﬀect was
most pronounced in compound 25, which displaced less than
40% of [3H]-CCR2-RA-[R] binding in CCR1 and less than
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10% in CCR2. The transformation of the ketone into an ester
might decrease the electron density on the carbonyl oxygen as
well as the acidity of the adjacent protons, thus weakening or
disrupting key hydrogen bonding interactions with Lys8x49 in
CCR224,28 or Arg8x49 in CCR1. The need of an acidic function
for intracellular antagonists has also been reported in a study
with N-benzylindole-2-carboxylic acids, where the authors
found a correlation between higher acidity and higher CCR2
aﬃnity.38 Finally, replacing the methyl group in R3 with a
phenyl group (26) had no eﬀect on CCR1 aﬃnity, while it
only displaced 37% of [3H]-CCR2-RA-[R] binding in CCR2.
Altogether, these ﬁndings indicate that bigger, more lipophilic
groups in R3 are better tolerated in CCR1, while in CCR2
methyl is preferred.
Modiﬁcations to the Phenyl Ring (R2, Table 2). In addition,
we explored diﬀerent N-aryl modiﬁcations in the phenyl ring
(R2, Table 2), starting with modiﬁcations in para position.
Removing the methyl group in 6 yielded compound 27, with
an unsubstituted phenyl group, which displaced less than 50%
of the radioligand in both receptors. Increasing the size of the
alkyl group from methyl (6) to ethyl (28) caused a 3-fold
decrease in CCR1 aﬃnity, while the aﬃnity in CCR2 was
maintained (28, 168 nM in CCR1 versus 66 nM in CCR2).
Adding an electron-donating methoxy group was unfavorable
for both receptors, as aﬃnities dropped to 260 nM in CCR1
and 217 nM in CCR2. In contrast, an electron-withdrawing
substituent (triﬂuoromethyl, 32) restored the aﬃnity to 92 nM
in CCR2, similar to our starting compound 6 and to 144 nM in
CCR1. The substitution of the para-methyl group with
halogens yielded derivatives with improved binding aﬃnities
in both receptors (30 and 31) but no gain in selectivity.
Substitution with a chlorine (30) or bromine atom (31) led to
a 4.5-fold increase in CCR2 aﬃnity compared with 6, with Ki
values around 20 nM regardless of the halogen. In the case of
CCR1, the bromine atom (31) led to a 2-fold increase
compared with 6 (31, 24 nM), while the smaller chlorine atom
did not aﬀect the aﬃnity much (30, 40 nM). Although not
synthesized in our study, Dasse et al. (2007)29 showed that the
para-ﬂuoro analogue performed worse in CCR2 than other
para-halogen derivatives. In this regard, from ﬂuoro to chloro
there is an important increase in polarity (σ), lipophilicity (π),
and size, whereas from chloro to bromo only lipophilicity and
size increase.39,40 Taken together, these results suggest that
lipophilicity and size of the halogen might be more important
in CCR1 than in CCR2, while electronegativity or polarity
could play a bigger role in CCR2.
Moving the substituents from the para to the meta position
resulted in poor aﬃnities for both receptors compared with
their para-substituted analogues. In CCR1, the meta-methyl
(33) and meta-chlorine (35) groups led to a 9-fold and 13-fold
decrease in aﬃnity, respectively; in CCR2, the aﬃnities
decreased 3-fold and 13-fold after the same substitutions.
The addition of a triﬂuoromethyl group in meta position (36)
also led to a 3-fold decrease in CCR2 aﬃnity compared with its
para-substituted analogue 32. In CCR1, 36 only displaced 25%
of [3H]-CCR2-RA-[R] binding at a concentration of 1 μM,
displaying the highest selectivity toward CCR2 in these series
of modiﬁcations. Also detrimental was the addition of a
ﬂuorine group in meta position (34), which led to less than
50% displacement of [3H]-CCR2-RA-[R] binding in both
receptors. Overall, substituents in the para position were more
favored in both receptors, especially halogen substituents, yet
none of the compounds displayed selectivity toward CCR1.
Similarly as reported by Dasse et al. (2007),29 attempts to
Table 2. Binding Aﬃnities of Compounds 6, 27−42 on Human CCR1 and Human CCR2
pKi ± SEM (Ki, nM)
a or displacement at 1 μM (%)b
compd R2 CCR1 CCR2
27 H 42% (41, 42) 45% (44, 45)
6 4-Me 7.26 ± 0.04 (56) 7.10 ± 0.03 (81)
28 4-Et 6.78 ± 0.02 (168) 7.19 ± 0.05 (66)
29 4-OMe 6.60 ± 0.07 (260) 6.67 ± 0.05 (217)
30 4-Cl 7.41 ± 0.05 (40) 7.73 ± 0.08 (19)
31 4-Br 7.62 ± 0.05 (24) 7.80 ± 0.12 (17)
32 4-CF3 6.86 ± 0.08 (144) 7.04 ± 0.02 (92)
33 3-Me 6.31 ± 0.07 (500) 6.58 ± 0.05 (265)
34 3-F 44% (45, 42) 47% (48, 47)
35 3-Cl 6.28 ± 0.08 (541) 6.62 ± 0.02 (239)
36 3-CF3 25% (23, 27) 6.54 ± 0.11 (305)
37 2-F, 4-Me 7.56 ± 0.10 (29) 7.44 ± 0.05 (37)
38 (CCR2-RA) 2-F, 4-Cl 7.82 ± 0.06 (15) 8.00 ± 0.09 (11)
39 2-F, 4-Br 7.98 ± 0.04 (11) 8.25 ± 0.02 (6)
40 3,4-diMe 7.37 ± 0.03 (43) 7.75 ± 0.02 (18)
41 3-Me, 4-Cl 7.51 ± 0.01 (31) 8.09 ± 0.08 (9)
42 3-F, 4-Me 7.32 ± 0.07 (49) 7.24 ± 0.02 (57)
apKi and Ki (nM) values obtained from [
3H]-CCR2-RA-[R] binding assays on U2OS membranes stably expressing human CCR1 or human CCR2.
Values are means ± standard error of the mean (SEM) of at least three independent experiments performed in duplicate. bPercent of [3H]-CCR2-
RA-[R] displacement by 1 μM compound. Values represent the mean of two independent experiments performed in duplicate.
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introduce diﬀerent substituents in the ortho position were
unsuccessful, thus we continued to explore diﬀerent combina-
tions of phenyl substituents.
As part of our SAR analysis, we synthesized compound 38
(also referred as CCR2-RA), which corresponds to the racemic
mixture of the radioligand [3H]-CCR2-RA-[R] used in this
study. This compound displayed an aﬃnity of 15 nM in CCR1
and 11 nM in CCR2, similar to the KD values obtained in
homologous displacement or saturation assays (Supporting
Information, Table S1). Replacing the para-chloro group in 38
with a methyl moiety (37), while keeping the ortho-ﬂuorine
group, led to an expected decrease in aﬃnity for both
receptors, as compound 6 with a methyl group in para position
performed worse than 30 with a chlorine atom in the same
position. When the para substituent was replaced with a
bromine atom (39), the aﬃnity was restored to 11 nM in
CCR1 and 6 nM in CCR2. Subsequent combinations of meta
and para substituents (40−42) generated compounds with
decreased CCR1 aﬃnities compared with 38, as expected from
the data on the monosubstituted meta analogues. Compound
41 displayed a slightly higher selectivity for CCR2 (9 nM in
CCR2 versus 31 nM in CCR1). Overall, disubstituted
derivatives performed better than the monosubstituted
compounds in both receptors; however, no clear trend in
selectivity was observed in these series.
In an attempt to improve both aﬃnity and selectivity for
CCR1, we decided to combine some of the best features
observed at R1, R2, and R3 positions: a disubstituted phenyl
ring with an ortho-ﬂuoro and para-bromo moieties for R2 in
order to retain the high aﬃnity of 39, a cyclopropyl group or
an unsubstituted phenyl ring at R3 (22 and 26) to gain
selectivity, and a meta-bromo phenyl ring at R1 (17) to further
improve selectivity for CCR1. These combinations resulted in
four ﬁnal compounds shown in Table 3 (43−46). To maintain
a high aﬃnity for CCR1, we kept the 2-ﬂuoro-4-bromophenyl
group at R2 constant, and we combined it with diﬀerent R1 and
R3 substituents. The combination with a cyclopropyl group at
R3 position (43) led to the highest CCR1 aﬃnity in our study
(Ki of 5 nM), but selectivity over CCR2 was reduced
compared with 22 (3-fold versus 8-fold). Replacing the
cyclopropyl group at R3 by a phenyl group (44) decreased
the aﬃnity for CCR1 by more than 5-fold compared with 43.
Compound 43, somewhat unexpectedly, bound to CCR2 with
an aﬃnity of 66 nM, more than 15-fold better than 26.
Replacing the cyclohexyl group at R1 (43) by a 3-bromo-
phenyl group (45) resulted in an improved selectivity over
CCR2, as this compound did not displace more than 50% of
[3H]-CCR2-RA-[R] binding at 1 μM, whereas it showed an
aﬃnity of 50 nM in CCR1. Finally, replacing the cyclopropyl
with a methyl group at R3 (46) maintained the aﬃnity for
CCR1 and restored the aﬃnity for CCR2 (65 nM in CCR1
and 216 nM in CCR2), with a concomitant loss of selectivity.
Functional Characterization of Selected Compounds.
Following the SAR analysis, four compounds (39, 41, 43,
and 45) were selected for further characterization in a G
protein-dependent functional assay in order to assess their
inhibitory potencies (pIC50) in both CCR1 and CCR2. The
four compounds were selected based on their aﬃnity and
selectivity proﬁle: compounds 43 and 39, with the highest
aﬃnity for either CCR1 or CCR2, respectively, compound 41,
with higher selectivity toward CCR2, and compound 45, with
higher selectivity toward CCR1. As a functional assay, we used
a previously reported [35S]GTPγS binding assay on U2OS-
CCR2 membranes, which had been applied in the functional
characterization of several allosteric and orthosteric CCR2
ligands.26 Similarly as reported by Zweemer et al. (2013),26
CCL2 stimulated [35S]GTPγS binding in a concentration-
dependent manner, displaying a potency of 5 nM in CCR2
(pEC50 = 8.3 ± 0.09, Figure 3a). Using the same assay
conditions, we characterized the G protein activation of CCL3
in U2OS-CCR1 membranes. In this assay, CCL3 induced
[35S]GTPγS binding in CCR1 with a higher potency than
CCL2 in CCR2 (1.3 nM, pEC50 = 8.9 ± 0.06) and with a
higher maximum eﬀect (Emax) (Figure 3a). It should be noted
that the potency of CCL3 in our study is lower than previously
reported,41 which might be related to the diﬀerences in cell
line and/or assay conditions.
For the antagonist assays, we used a submaximal EC80
concentration of CCL3 (8 nM) and CCL2 (20 nM) in
CCR1 or CCR2, respectively, in order to evoke 80%
stimulation of [35S]GTPγS binding. Although all compounds
were able to inhibit CCL3- or CCL2-induced G protein
activation, their potencies (IC50) ranged between 30 nM to 8
μM (Table 4 and Figure 3b,c). In CCR2, the potency of the
compounds increased in the same order observed for aﬃnity
(Figure 3c, 45 < 43 < 41 < 39). In CCR1, 39 displayed the
highest potency (590 nM), followed by 43 (950 nM), contrary
to their binding aﬃnity (Figure 3b, 43 > 39). In addition, the
moderate selectivity observed in the binding assays was lost in
this functional assay: except for 45, all compounds were more
potent inhibitors of CCR2 than CCR1, as their potencies were
3-fold (43), 19-fold (39), or 48-fold (41) lower in CCR1.
Upon comparison of potencies in the [35S]GTPγS assay and
the aﬃnities in the [3H]-CCR2-RA-[R] binding assay, we
observed that all compounds displayed between 5 and 10-fold
diﬀerence between assays in CCR2 (Tables 2−4), in
agreement with previous characterization of CCR2-RA-[R]
on this receptor.26 In contrast, all compounds displayed at least
a 50-fold diﬀerence between assays when tested on CCR1.
Such lack of correlation between apparent potencies and
binding aﬃnities in CCR1 might be dependent on the assay
conditions used, G protein concentrations, or the chemokine
Table 3. Binding Aﬃnities of Compounds 43−46 on
Human CCR1 and Human CCR2
pKi ± SEM (Ki, nM)
a or displacement at 1
μM (%)b
compd R1 R3 CCR1 CCR2
43 c-hexyl c-propyl 8.27 ± 0.02 (5) 7.82 ± 0.04 (15)
44 c-hexyl Ph 7.56 ± 0.04 (28) 7.18 ± 0.03 (66)
45 3-Br Ph c-propyl 7.30 ± 0.01 (50) 45% (49, 42)
46 3-Br Ph Me 7.19 ± 0.02 (65) 6.67 ± 0.01 (216)
apKi and Ki (nM) values obtained from [
3H]-CCR2-RA-[R] binding
assays on U2OS membranes stably expressing human CCR1 or
human CCR2. Values are means ± standard error of the mean (SEM)
of at least three independent experiments performed in duplicate.
bPercent of [3H]-CCR2-RA-[R] displacement by 1 μM compound.
Values represent the mean of two independent experiments
performed in duplicate.
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used in this study; thus, further studies are warranted to fully
characterize these ligands for their selectivity.
In CCR1, all compounds behaved as inverse agonists, as
they all signiﬁcantly decreased the basal activity of CCR1 at the
highest concentration tested (Supporting Information, Figure
S3a). In this regard, it was previously demonstrated that CCR1
exhibits constitutive activity leading to ligand-independent G
protein-activation, β-arrestin recruitment, and receptor inter-
nalization,42 which points to the development of inverse
agonists as a potential therapeutic option for inﬂammatory
diseases. Yet, only BX-47135 has been reported to act as inverse
agonist in CCR1.42 This prompted us to further characterize
these compounds as inverse agonists in CCR1 by measuring
their inhibitory potency in absence of the agonist CCL3
(Supporting Information, Figure S3b and Table S2).
Compounds 39 and 41 were more potent inverse agonists
than antagonists, displaying a 3-fold and almost 10-fold higher
potency, respectively, as inverse agonists. As such, their
potencies as inverse agonists were more comparable to their
binding aﬃnities (Table 2 and Supporting Information, Table
S2). In contrast, 43 and 45 showed similar potencies when
measured in the absence or presence of CCL3 and thus
displayed more than 130-fold diﬀerence between functional
and binding assays (Table 2 and Supporting Information,
Table S2). Interestingly, both compounds 43 and 45 have a
cyclopropyl in the R3 position while 39 and 41 have a methyl
group (Tables 2 and 3), which suggests that this larger group
might be responsible for the diﬀerence in their eﬃcacy and
functional proﬁle. Moreover, most compounds displayed
pseudo-Hill slopes of less than unity in CCR1 when tested
in the presence or absence of CCL3 (Table 4 and Supporting
Information, Table S2), indicative of a more complex
mechanism of inhibition, combining negative allosteric
modulation and inverse agonism.43 Of note, the basal levels
of constitutive activity in the [35S]GTPγS assay are very
dependent on the assay conditions used, such as GDP
concentrations. Yet, at a single concentration (100 μM) tested,
all compounds consistently decreased the basal activity in
CCR1 after varying GDP concentrations. For instance,
compound 41 decreased basal activity by 22% (1 μM GDP),
26% (10 μM GDP), and 25% (20 μM GDP) (data not
shown). To the best of our knowledge, these compounds
represent the ﬁrst intracellular ligands with demonstrated
inverse agonism in CCR1. Both 45 and 43 decreased the basal
activity of CCR2 to a similar or smaller level than in CCR1
(45, maximal decrease of 58%; 43, maximal decrease of 27%),
indicative of inverse agonism (Supporting Information, Figure
S3a). However, no constitutive activity has been reported for
CCR2, with only one constitutively active mutant (CAM)
described so far.44 In fact, Gilliland et al. (2013) showed that
CCR2 was not able to induce ligand-independent cell
migration or to constitutively associate with β-arrestin,
pointing to a lack of constitutive activity.42 Moreover, several
classes of orthosteric and allosteric CCR2 ligands did not show
evidence of inverse agonism when previously tested in a similar
[35S]GTPγS binding assay.26 Thus, the inverse agonism
observed in this study might be the consequence of the
expression level, ligand concentration, and/or assay conditions
employed, so further research is warranted to investigate
ligand-independent signaling in CCR2.
■ CONCLUSIONS
In this study, we have characterized [3H]-CCR2-RA-[R], a
high-aﬃnity intracellular antagonist previously described for
CCR2,26 in both CCR1 and CCR2, which allowed us to
conclude that this radioligand binds to CCR1 with a similar
high aﬃnity. By characterizing this radioligand in CCR1, we
have provided evidence that CCR1 possesses an intracellular
binding site that can be used for the design of noncompetitive
compounds. In addition, this intracellular radioligand allowed
us to explore the SAR of a series of pyrrolone derivatives in
both CCR1 and CCR2. Although some of these derivatives
had been previously described for CCR2, their characterization
in CCR1 had not been reported. With the SAR analysis we
learned that introduction of bulkier and more lipophilic groups
Figure 3. (a) [35S]GTPγS binding upon stimulation of U2OS-CCR1
and U2OS-CCR2 by increasing concentrations of CCL3 and CCL2,
respectively. In both cases, the response was corrected by subtracting
the basal activity (approximately 8000 dpm for both CCR1 and
CCR2). (b) Inhibition of CCL3-induced [35S]GTPγS binding by
compounds 39, 41, 43, and 45 in U2OS-CCR1. (c) Inhibition of
CCL2-induced [35S]GTPγS binding by compounds 39, 41, 43, and
45 in U2OS-CCR2. The level of basal activity in U2OS-CCR1 and
U2OS-CCR2 is indicated by a dashed line. In all cases, data shown are
mean ± SEM of at least three experiments performed in duplicate.
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at R1 and R3 positions was better tolerated in CCR1, allowing
us to obtain better selectivity for this receptor. The high
conservation between the intracellular pockets of CCR1 and
CCR2 prevented us from ﬁnding high selectivity in these series
of compounds but allowed us to ﬁnd several potential dual-
target antagonists. Finally, characterization of four selected
compounds in a functional assay allowed us to determine their
functional eﬀects as antagonists in CCR2 and inverse agonists
in the constitutively active CCR1, which opens up a novel
avenue to modulate these receptors in inﬂammatory diseases.
In addition, this highly conserved binding site might allow the
design of both selective and multitarget inhibitors for
chemokine receptors beyond CCR1 and CCR2.
■ EXPERIMENTAL SECTION
Chemistry: General Methods. All solvents and reagents were
purchased from commercial sources and were of analytical grade.
Demineralized water is simply referred to as H2O, as was used in all
cases unless stated otherwise (i.e., brine). 1H NMR spectra were
recorded on a Bruker AV 400 liquid spectrometer (1H NMR, 400
MHz) at ambient temperature. Chemical shifts are reported in parts
per million (ppm), are designated by δ, and are downﬁeld to the
internal standard tetramethylsilane (TMS) in CDCl3. Coupling
constants are reported in Hz and are designated as J. As a
representative example of the obtained 1H NMR spectra, Supporting
Information, Figure S4 shows the 1H NMR spectrum of compound
43. Analytical purity of the ﬁnal compounds was determined by high
pressure liquid chromatography (HPLC) with a Phenomenex Gemini
3 × C18 110A column (50 mm × 4.6 mm, 3 μm), measuring UV
absorbance at 254 nm. Sample preparation and HPLC method was,
unless stated otherwise, as follows: 0.3−0.8 mg of compound was
dissolved in 1 mL of a 1:1:1 mixture of CH3CN/H2O/tBuOH and
eluted from the column within 15 min, with a three component
system of H2O/CH3CN/1% TFA in H2O, decreasing polarity of the
solvent mixture in time from 80/10/10 to 0/90/10. All compounds
showed a single peak at the designated retention time and are at least
95% pure. Liquid chromatography−mass spectrometry (LC−MS)
analyses were performed using Thermo Finnigan Surveyor−LCQ
Advantage Max LC−MS system and a Gemini C18 Phenomenex
column (50 mm × 4.6 mm, 3 μm). The elution method was set up as
follows: 1−4 min isocratic system of H2O/CH3CN/1% TFA in H2O,
80:10:10, from the fourth minute, a gradient was applied from
80:10:10 to 0:90:10 within 9 min, followed by 1 min of equilibration
at 0:90:10 and 1 min at 80:10:10. Thin-layer chromatography (TLC)
was routinely performed to monitor the progress of reactions, using
aluminum coated Merck silica gel F254 plates. Puriﬁcation by column
chromatography was achieved by use of Grace Davison Davisil silica
column material (LC60A 30−200 μm). Yields and reaction
conditions were not optimized. Additionally, all compounds were
screened using FAF-Drugs445,46 in order to detect potential pan-assay
interference compounds (PAINS). None of the compounds was
identiﬁed as PAINS after application of three diﬀerent ﬁlters based on
Baell et al.47
General Procedure for the Synthesis of Compounds 6−23,
26−46.33 The respective aldehyde 1a−l (1.0 equiv), aniline 2a−q
(1.0 equiv), and ethyl 2,4-dioxo-butanoate analogue 3a−i (1.0 equiv)
were dissolved in acetic acid (2.5 mL/mmol) and heated at 95 °C for
2−4 h under a nitrogen atmosphere. Upon completion of the reaction
(TLC 1/7 EtOAct/petroleum ether), acetic acid was removed under
reduced pressure, the residue was triturated with Et2O and stirred for
30 min, after which the pure product was collected by ﬁltration.
4-Acetyl-5-cyclohexyl-3-hydroxy-1-(4-methylphenyl)-1,5-dihy-
dro-2H-pyrrol-2-one (6).33 Started from cyclohexane carboxaldehyde
1a (243 μL, 2.00 mmol, 1.00 equiv), 4-methylaniline (214 mg, 2.00
mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (251 μL, 2.00
mmol, 1.00 equiv) in 5 mL of acetic acid. Yield: 287 mg, 46%, white
solid. 1H NMR (400 MHz, DMSO): δ 7.38 (d, J = 8.4 Hz, 2H), 7.24
(d, J = 8.4 Hz, 2H), 4.99 (d, J = 1.2 Hz, 1H), 2.43 (s, 3H), 2.32 (s,
3H), 1.83 (t, J = 11.2 Hz, 1H), 1.65−1.56 (m, 1H), 1.52−1.27 (m,
4H), 0.53 (qd, J = 12.4, 2.8 Hz, 1H) ppm. MS [ESI + H]+: 313.93.
4-Acetyl-5-cycloheptyl-3-hydroxy-1-(4-methylphenyl)-1,5-dihy-
dro-2H-pyrrol-2-one (7).32 Started from cycloheptylcarboxaldehyde
1b48 (375 mg, 3.00 mmol, 1.00 equiv), 4-methylaniline 2b (321 mg,
3.00 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (377 μL,
3.00 mmol, 1.00 equiv) in 7.5 mL of acetic acid. Puriﬁed by
recrystallization from a mixture of EtOAc and petroleum ether. Yield:
102 mg, 13%, oﬀ-white solid. 1H NMR (400 MHz, CDCl3): δ 7.26−
7.22 (m, 4H), 4.95 (d, J = 1.6 Hz, 1H), 2.54 (s, 3H), 2.38 (s, 3H)
ppm, 2.09−2.03 (m, 1H), 1.61−1.47 (m, 4H), 1.46−1.32 (m, 4H),
1.31−1.12 (m, 4H), 0.80 (qd, J = 10.8, 3.2 Hz, 1H) ppm. MS: [ESI +
H]+: 328.13.
4-Acetyl-5-cyclooctyl-3-hydroxy-1-(4-methylphenyl)-1,5-dihy-
dro-2H-pyrrol-2-one (8).32 Started from cyclooctylcarboxaldehyde 1c
(648 mL, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474 mg, 4.42
mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42
mmol, 1.00 equiv) in 10 mL of acetic acid. Puriﬁed by column
chromatography using as eluent 1/6 EtOAc/petroleum ether. Yield:
118 mg, 8%, white solid. 1H NMR (400 MHz, CDCl3): δ 7.26−7.21
(m, 4H), 4.90 (d, J = 1.6 Hz, 1H), 2.53 (s, 3H), 2.37 (s, 3H), 2.22−
2.14 (m, 1H), 1.62−1.52 (m, 1H), 1.50−1.15 (m, 13H) 0.89−0.78
(m, 1H) ppm. MS: [ESI + H]+: 342.20.
4-Acetyl-3-hydroxy-1-(4-methylphenyl)-5-phenyl-1,5-dihydro-
2H-pyrrol-2-one (9).32 Started from benzaldehyde 1d (449 mL, 4.42
mmol, 1.00 equiv), 4-methylaniline 2b (474 mg, 4.42 mmol, 1.00
equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00
equiv) in 10 mL of acetic acid. Yield: 867 mg, 64%, oﬀ-white solid. 1H
NMR (400 MHz, CDCl3): δ 7.28−7.24 (m, 5H), 7.22 (d, J = 6.0 Hz,
Table 4. Functional Characterization of Compounds 37, 39, 41, and 43 in U2OS-CCR1 and U2OS-CCR2 Using a [35S]GTPyS
Binding Assay
inhibition of [35S]GTPyS bindinga
CCR1b CCR2c
compd pIC50 ± SEM (IC50, μM) Hill slope pIC50 ± SEM (IC50, μM) Hill slope
39 6.26 ± 0.10 (0.59)*** −0.62 ± 0.05** 7.57 ± 0.08 (0.03) −0.94 ± 0.18
41 5.73 ± 0.09 (1.94)*** −0.72 ± 0.08* 7.47 ± 0.10 (0.04) −0.88 ± 0.13
43 6.03 ± 0.04 (0.95) −0.73 ± 0.02* 6.54 ± 0.16 (0.33) −0.80 ± 0.13
45 5.07 ± 0.05 (8.64) −0.93 ± 0.01 5.06 ± 0.05 (8.77) −1.20 ± 0.08
aAll values are means ± SEM of at least three independent experiments performed in duplicate. Unpaired t-test analysis with Welch’s correction
was performed to analyze diﬀerences in pIC50 values between receptors, with diﬀerences noted as ***, p < 0.001. One-Way ANOVA with
Dunnett’s posthoc test was performed to compare pseudo-Hill slopes against compound 45, which showed a pseudo-Hill slope of approximately
unity in both receptors, with signiﬁcant diﬀerences displayed as *, p < 0.05; **, p < 0.01. bInhibition of CCL3-induced [35S]GTPyS binding in
U2OS membranes stably expressing human CCR1. A concentration of 8 nM CCL3 was used in the assays to evoke an 80% response. cInhibition of
CCL2-induced [35S]GTPyS binding in U2OS membranes stably expressing human CCR2. A concentration of 20 nM CCL2 was used in the assays
to evoke an 80% response.
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2H), 7.07 (d, J = 8.0 Hz, 2H), 5.75 (s, 1H), 2.49 (s, 3H), 2.16 (s, 3H)
ppm. MS [ESI + H]+: 308.00.
4-Acetyl-3-hydroxy-5-(4-methylphenyl)-1-(4-methylphenyl)-1,5-
dihydro-2H-pyrrol-2-one (10). Started from 4-methylbenzaldehyde
1e (521 mL, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474 mg,
4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL,
4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. Puriﬁed by
recrystallization from acetone/hexanes. Yield: 257 mg, 18% yellowish
solid. 1H NMR (400 MHz, DMSO-d6): δ 7.42 (d, J = 8.4 Hz, 2H),
7.12−7.04 (m, 4H), 6.98 (d, J = 8.0 Hz, 2H), 5.94 (s, 1H), 2.30 (s,
3H), 2.19 (s, 3H), 2.16 (s, 3H) ppm. MS [ESI + H]+: 322.00.
4-Acetyl-3-hydroxy-5-(4-methoxyphenyl)-1-(4-methylphenyl)-
1,5-dihydro-2H-pyrrol-2-one (11).49 Started from 4-methoxybenzal-
dehyde 1f (527 mL, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474
mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554
μL, 4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. The desired
product was obtained by column chromatography using a gradient of
1/6 EtOAc/petroleum ether to 1/3 EtOAc/petroleum ether, yielding
34 mg, 2% as an oﬀ-white solid. 1H NMR (400 MHz, DMSO-d6): δ
7.42 (d, J = 8.4 Hz, 2H), 7.12 (d, J = 8.4 Hz, 2H), 7.08 (d, J = 8.8 Hz,
2H), 6.73 (d, J = 8.8 Hz, 2H) 5.93 (s, 1H), 3.64 (s, 3H), 2.30 (s, 3H),
2.20 (s, 3H) ppm. MS [ESI + H]+: 337.80.
4-Acetyl-5-(4-chlorophenyl)-3-hydroxy-1-(4-methylphenyl)-1,5-
dihydro-2H-pyrrol-2-one (12).32 Started from 4-chlorobenzaldehyde
1g (621 mg, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474 mg,
4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL,
4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. The desired product
was obtained by column chromatography using 1/6 EtOAc/
petroleum ether as eluent, yielding 96 mg, 6% as a white solid. 1H
NMR (400 MHz, DMSO- d6): δ 7.43 (d, J = 8.4 Hz, 2H), 7.30−7.18
(m, 4H), 7.08 (d, J = 8.4 Hz, 2H), 5.98 (s, 1H), 2.30 (s, 3H), 2.20 (s,
3H) ppm. MS [ESI + H]+: 342.00.
4-Acetyl-5-(4-bromophenyl)-3-hydroxy-1-(4-methylphenyl)-1,5-
dihydro-2H-pyrrol-2-one (13).32 Started from 4-bromobenzaldehyde
1h (818 mg, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474 mg,
4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL,
4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. Yield: 1.23 g, 72%,
yellowish solid. 1H NMR (400 MHz, CDCl3): δ 7.39 (d, J = 8.8 Hz,
2H), 7.25 (d, J = 8.8 Hz, 2H), 7.11−7.08 (m, 4H), 5.73 (s, 1H), 2.27
(s, 3H), 2.23 (s, 3H) ppm. MS [ESI + H]+: 387.93.
4-Acetyl-3-hydroxy-5-(3-methylphenyl)-1-(4-methylphenyl)-1,5-
dihydro-2H-pyrrol-2-one (14). Started from 3-methylbenzaldehyde 1i
(600 mg, 5.00 mmol, 1.00 equiv), 4-methylaniline 2b (536 mg, 5.00
mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (627 μL, 5.00
mmol, 1.00 equiv) in 12 mL of acetic acid. Yield: 560 mg, 35%, white
solid. 1H NMR (400 MHz, DMSO- d6): δ 7.43 (d, J = 8.4 Hz, 2H),
7.11−7.05 (m, 3H), 7.02 (d, J = 8.4 Hz, 2H), 6.93 (d, J = 7.2 Hz,
1H), 5.94 (s, 1H), 2.31 (s, 3H), 2.19 (s, 3H), 2.18 (s, 3H) ppm. MS
[ESI + H]+: 321.93.
4-Acetyl-3-hydroxy-5-(3-methoxyphenyl)-1-(4-methylphenyl)-
1,5-dihydro-2H-pyrrol-2-one (15). Started from 3-methoxylbenzalde-
hyde 1j (681 mg, 5.00 mmol, 1.00 equiv), 4-methylaniline 2b (536
mg, 5.00 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (627
μL, 5.00 mmol, 1.00 equiv) in 12 mL of acetic acid. Yield: 1.27 g,
75%, white solid. 1H NMR (400 MHz, DMSO- d6): δ 7.44 (d, J = 8.4
Hz, 2H), 7.12−7.07 (m, 3H), 6.79 (s, 1H), 6.75 (d, J = 0.8 Hz, 1H),
6.69 (dd, J = 8.0, 2.2 Hz, 1H), 5.97 (s, 1H), 3.65 (s, 3H), 2.32 (s,
3H), 2.20 (s, 3H) ppm. MS [ESI + H]+: 337.39.
4-Acetyl-5-(3-chlorophenyl)-3-hydroxy-1-(4-methylphenyl)-1,5-
dihydro-2H-pyrrol-2-one (16). Started from 3-chlorobenzaldehyde
1k (703 mg, 5.00 mmol, 1.00 equiv), 4-methylaniline 2b (536 mg,
5.00 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (627 μL,
5.00 mmol, 1.00 equiv) in 12 mL of acetic acid. Yield: 619 mg, 36%,
light-yellow solid. 1H NMR (400 MHz, CDCl3): δ 7.28 (d, J = 8.4 Hz,
2H), 7.21−7.18 (m, 3H), 7.17−7.13 (m, 1H), 7.10 (d, J = 8.4 Hz,
2H), 5.75 (s, 1H), 2.29 (s, 3H), 2.27 (s, 3H) ppm. MS [ESI + H]+:
341.80.
4-Acetyl-5-(3-bromophenyl)-3-hydroxy-1-(4-methylphenyl)-1,5-
dihydro-2H-pyrrol-2-one (17). Started from 3-bromobenzaldehyde 1l
(925 mg, 5.00 mmol, 1.00 equiv), 4-methylaniline 2b (536 mg, 5.00
mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (627 μL, 5.00
mmol, 1.00 equiv) in 12 mL of acetic acid. Yield: 993 mg, 51%, brown
solid. 1H NMR (400 MHz, DMSO-d6): δ 7.48 (t, J = 1.6 Hz, 1H),
7.44 (d, J = 8.4 Hz, 2H), 7.34−7.30 (m, 1H), 7.20 (dt, J = 8.0, 1.6 Hz,
1H), 7.14 (t, J = 7.6 Hz, 1H), 7.10 (d, J = 8.4 Hz, 2H), 6.02 (s, 1H),
2.33 (s, 3H), 2.20 (s, 3H) ppm. MS [ESI + H]+: 386.67.
5-Cyclohexyl-3-hydroxy-4-propionyl-1-(4-methylphenyl)-1,5-di-
hydro-2H-pyrrol-2-one (18). Started from cyclohexane carboxalde-
hyde 1a (129 mg, 1.15 mmol, 1.00 equiv), 4-methylaniline 2b (123
mg, 1.15 mmol, 1.00 equiv), and ethyl 2,4-dioxohexanoate50 3b (198
mg, 1.15 mmol, 1.00 equiv) in 3 mL of acetic acid. Yield: 65 mg, 19%,
white solid. 1H NMR (400 MHz, CDCl3): δ 7.31−7.23 (m, 4H), 4.96
(s,1H), 2.95−2.82 (m, 2H), 2.38 (s, 3H), 1.90 (t, J = 10.8 Hz, 1H),
1.66−1.54 (m, 4H), 1.43−1.41 (m, 1H), 1.17 (t, J = 7.2 Hz, 3H),
1.09−1.03 (m, 3H), 0.98−0.86 (m, 1H), 0.71−0.61 (m, 1H) ppm.
MS [ESI + H]+: 328.13.
4-Butyryl-5-cyclohexyl-3-hydroxy-1-(4-methylphenyl)-1,5-dihy-
dro-2H-pyrrol-2-one (19).32 Started from cyclohexane carboxalde-
hyde 1a (605 μL, 5.00 mmol, 1.00 equiv), 4-methylaniline 2b (536
mg, 5.00 mmol, 1.00 equiv), and ethyl 2,4-dioxoheptanoate34 3c (198
mg, 1.15 mmol, 1.00 equiv) in 12 mL of acetic acid. Yield: 669 mg
(39%) as a white solid. 1H NMR (400 MHz, DMSO): δ 7.39 (d, J =
8.4 Hz, 2H), 7.24 (d, J = 8.0 Hz, 2H), 5.02 (s, 1H), 2.89−2.70 (m,
2H), 2.32 (s, 3H), 1.84−1.78 (m, 1H), 1.61−1.32 (m, 7H), 0.97−
0.80 (m, 6H), 0.80−0.73 (m, 1H), 0.57−0.48 (m, 1H) ppm. MS [ESI
+ H]+: 341.87.
4-Pentanoyl-5-cyclohexyl-3-hydroxy-1-(4-methylphenyl)-1,5-di-
hydro-2H-pyrrol-2-one (20). Started from cyclohexane carboxalde-
hyde 1a (266 mg, 2.37 mmol, 1.00 equiv), 4-methylaniline 2b (253
mg, 2.37 mmol, 1.00 equiv), and ethyl 2,4-dioxooctanoate34 3d (475
mg, 2.37 mmol, 1.00 equiv) in 5 mL of acetic acid. Yield: 237 mg,
28%, white solid. 1H NMR (400 MHz, DMSO): δ 12.02 (br s 1H),
7.39 (d, J = 8.0 Hz, 2H), 7.24 (d, J = 7.6 Hz, 2H), 5.02 (s, 1H), 2.92−
2.73 (m, 2H), 2.32 (s, 3H), 1.85−1.75 (m, 1H), 1.58−1.28 (m, 9H),
0.91−0.65 (m, 7H) 0.57−0.50 (m, 1H) ppm. MS [ESI + H]+: 356.00.
5-Cyclohexyl-3-hydroxy-4-isobutyryl-1-(4-methylphenyl)-1,5-di-
hydro-2H-pyrrol-2-one (21). Started from cyclohexane carboxalde-
hyde 1a (535 μL, 4.42 mmol, 1.00 equiv), 4-methylaniline 2b (474
mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxo-5-methylhexanoate
3e (823 mg, 4.42 mmol, 1.00 equiv) in 10 mL of acetic acid. Yield:
255 mg, 17%, white solid. 1H NMR (400 MHz, DMSO-d6): δ 12.07
(br s, 1H), 7.40 (d, J = 7.6 Hz, 2H), 7.24 (d, J = 7.6 Hz, 2H), 5.03 (d,
J = 1.6 Hz, 1H), 3.44−3.41 (m, 1H), 2.32 (s, 3H), 1.80−1.70 (m,
1H), 1.62−1.59 (m, 1H), 1.46−1.37 (m, 4H), 1.09 (d, J = 6.8 Hz,
3H), 1.02 (d, J = 6.8 Hz, 3H), 0.97−0.77 (m, 4H), 0.59−0.53 (m,
1H) ppm. MS [ESI + H]+: 342.13.
5-Cyclohexyl-4-(cyclopropanecarbonyl)-3-hydroxy-1-(4-methyl-
phenyl)-1,5-dihydro-2H-pyrrol-2-one (22). Started from cyclohexane
carboxaldehyde 1a (605 μL, 5.00 mmol, 1.00 equiv), 4-methylaniline
2b (550 μL, 5.00 mmol, 1.00 equiv), and ethyl 4-cyclopropyl-2,4-
dioxobutanoate51 3f (920 mg, 5.00 mmol, 1.00 equiv) in 10 mL of
AcOH. Yield: 60 mg, 4%, white solid. 1H NMR (400 MHz, MeOD):
δ 7.34 (d, J = 8.4 Hz, 2H), 7.27 (d, J = 7.6 Hz, 2H), 5.01 (d, J = 2.0
Hz, 1H), 3.01−2.95 (m, 1H), 2.38 (s, 3H), 1.88 (t, J = 10.4 Hz, 1H),
1.72−1.64 (m, 1H), 1.60−1.48 (m, 3H), 1.41 (d, J = 11.2 Hz, 1H),
1.04−0.86 (m, 8H), 0.72−0.62 (m, 1H) ppm. MS [ESI + Na]+:
363.10.
5-Cyclohexyl-3-hydroxy-1-(4-methylphenyl)-4-pivaloyl-1,5-dihy-
dro-2H-pyrrol-2-one (23).32 Started from cyclohexane carboxalde-
hyde 1a (121 μL, 1.00 mmol, 1.00 equiv), 4-methylaniline 2b (107
mg, 1.00 mmol, 1.00 equiv), and ethyl 5,5-dimethyl-2,4-dioxohex-
anoate 3g (175 μL, 1.00 mmol, 1.00 equiv) in 3 mL of acetic acid.
Yield: 20 mg, 6%, white solid. 1H NMR (400 MHz, DMSO-d6): δ
7.41 (d, J = 8.4 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 5.11 (d, J = 2.2 Hz,
1H), 2.32 (s, 3H), 1.63−1.58 (m, 2H), 1.52−1.46 (m, 3H), 1.31−
1.28 (m, 1H) 1.25 (s, 9H) 1.01−0.69 (m, 4H), 0.69−0.59 (m, 1H)
ppm. MS [ESI + H]+: 356.13.
Ethyl 2-Cyclohexyl-4-hydroxy-5-oxo-1-(4-methylphenyl)-2,5-di-
hydro-1H-pyrrole-3-carboxylate (24).29 Sodium 1,4-diethoxy-1,4-
dioxobut-2-en-2-olate (1.25 g, 6.00 mmol) was dissolved in 25 mL
of H2O, and 25 mL of Et2O was added. The mixture was acidiﬁed to
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pH 2 with 6 M HCl (aq) and was extracted with Et2O from the
aqueous phase, dried over MgSO4, and concentrated in vacuo,
yielding 1.05 g, 4.97 mmol, 83% diethyl 2-oxosuccinate as a yellow
oil.52
Diethyl 2-oxosuccinate 3h (1.05 g, 4.97 mmol, 1.12 equiv) was
added to a mixture of cyclohexane carboxaldehyde 1a (534 μL, 4.42
mmol, 1.00 equiv) and 4-methylaniline 2b (474 mg, 4.42 mmol, 1.00
equiv) in 10 mL of dry THF and stirred at room temperature
overnight. The reaction mixture was concentrated in vacuo, Et2O was
added, and the white precipitate was collected by ﬁltration. Yield: 400
mg, 26%, white solid. 1H NMR (400 MHz, CDCl3): δ 11.24 (s, 1H),
7.40 (d, J = 8.4 Hz, 2H), 7.24 (d, J = 8.4 Hz, 2H), 5.00 (d, J = 1.8 Hz,
1H), 4.32−4.13 (m, 2H), 2.32 (s, 3H), 1.85−1.76 (m, 1H), 1.66−
1.59 (m, 1H), 1.56−1.44 (m, 3H), 1.32 (d, J = 12.0 Hz, 1H), 1.26 (t,
J = 7.2 Hz, 3H), 1.06−0.75 (m, 4H), 0.63−0.53 (m, 1H) ppm. MS
[ESI + H]+: 344.07.
Isopropyl 2-Cyclohexyl-4-hydroxy-5-oxo-1-(4-methylphenyl)-
2,5-dihydro-1H-pyrrole-3-carboxylate (25). Ester 22 (343 mg, 1.00
mmol, 1.00 equiv) and p-toluenesulfonic acid (172 mg, 1.00 mmol,
1.00 equiv) were dissolved in 10 mL of 2-propanol, and the reaction
mixture was reﬂuxed for 48 h. The solvent was removed under
reduced pressure, and the crude product was dissolved in 50 mL of
EtOAc and washed 3× with H2O, dried over MgSO4, ﬁltered, and
concentrated under reduced pressure. The crude product was puriﬁed
by column chromatography (4/1 EtOAc/petroleum ether) and
yielded 150 mg, 9.5%, brownish solid. 1H NMR (400 MHz,
CDCl3): δ 9.33 (s, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.22 (d, J = 8.4
Hz, 2H), 5.31−5.23 (m, 1H), 4.79 (d, J = 2.0 Hz, 1H), 2.37 (s, 3H),
1.88 (td, J = 9.6, 2.8 Hz, 1H), 1.73−1.66 (m, 1H), 1.63−1.50 (m,
3H), 1.38 (d, J = 6.8 Hz, 6H), 1.29−1.19 (m, 1H), 1.13−0.90 (m,
4H), 0.74−0.64 (m, 1H) ppm. MS [ESI + H]+: 357.93.
4-Benzoyl-5-cyclohexyl-3-hydroxy-1-(4-methylphenyl)-1,5-dihy-
dro-2H-pyrrol-2-one (26). Started from cyclohexane carboxaldehyde
1a (484 μL, 4.00 mmol, 1.00 equiv), 4-methylaniline 2b (428 mg,
4.00 mmol, 1.00 equiv), and ethyl 2,4-dioxo-4-phenylbutanoate53 3i
(880 mg, 4.00 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 53 mg,
4%, white solid. 1H NMR (400 MHz, DMSO- d6): δ 7.85 (d, J = 7.6
Hz, 2H), 7.69−7.62 (m, 1H), 7.58−7.52 (m, 2H), 7.49 (d, J = 8.0 Hz,
2H), 7.29 (d, J = 8.4 Hz, 2H), 5.32 (s, 1H), 2.35 (s, 3H), 1.73−1.62
(m, 2H), 1.58−1.51 (m, 2H), 1.49−1.37 (m, 2H), 1.05−0.94 (m,
1H), 0.88−0.74 (m, 4H) ppm. MS [ESI + H]+: 375.93.
4-Acetyl-5-cyclohexyl-3-hydroxy-1-phenyl-1,5-dihydro-2H-pyr-
rol-2-one (27).32 Started from cyclohexane carboxaldehyde 1a (534
μL, 4.42 mmol, 1.00 equiv), aniline 2a (400 μL, 4.42 mmol, 1.00
equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00
equiv) in 10 mL of AcOH. Yield: 1.00 g, 76%, yellow solid. 1H NMR
(400 MHz, CDCl3): δ 7.47−7.44 (m, 4H), 7.32−7.28 (m, 1H), 4.99
(d, J = 2.0 Hz, 1H), 2.54 (s, 3H), 1.97−1.90 (m, 1H), 1.69−1.66 (m,
1H), 1.59−1.48 (m, 3H), 1.45−1.41 (m, 1H), 1.10−0.99 (m, 3H),
0.92−0,86 (m, 1H), 0.63 (qd, J = 9.2, 3.6 Hz, 1H) ppm. MS [ESI +
H]+: 300.07.
4-Acetyl-5-cyclohexyl-1-(4-ethylphenyl)-3-hydroxy-1,5-dihydro-
2H-pyrrol-2-one (28).32 Started from cyclohexane carboxaldehyde 1a
(534 μL, 4.42 mmol, 1.00 equiv), 4-ethylaniline 2c (553 μL, 4.42
mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42
mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 134 mg, 9%, light-yellow
solid. 1H NMR (400 MHz, CDCl3): δ 7.32 (d, J = 8.4 Hz, 2H), 7.25
(d, J = 6.4 Hz, 2H), 4.94 (s, 1H), 2.68 (q, J = 7.6 Hz, 2H) 2.54 (s,
3H), 1.95−1.90 (m, 1H), 1.68−1.66 (m, 1H), 1.67−1.51 (m, 3H),
1.43−1.41 (m, 1H), 1.26 (t, J = 7.6 Hz, 3H), 1.10−0.98 (m, 4H),
0.90−0.87 (m, 1H), 0.69−0.60 (m, 1H) ppm. MS [ESI + H]+:
328.13.
4-Acetyl-5-cyclohexyl-3-hydroxy-1-(4-methoxyphenyl)-1,5-dihy-
dro-2H-pyrrol-2-one (29).32 Started from cyclohexane carboxalde-
hyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 4-methoxyaniline 2d (560
mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554
μL, 4.42 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 805 mg, 56%,
light-yellow solid. 1H NMR (400 MHz, DMSO-d6): δ 7.41 (d, J = 8.8
Hz, 2H), 7.00 (d, J = 9.2 Hz, 2H), 4.96 (d, J = 1.2 Hz, 1H), 3.77 (s,
3H), 2.43 (s, 3H), 1.86−1.80 (m,1H), 1.60−1.58 (m, 1H), 1.40−1.37
(m, 2H), 1.35−1.32 (m, 2H), 0.99−0.91 (m, 3H), 0.87−0.75 (m,
1H), 0.58−0.55 (m, 1H) ppm. MS [ESI + H]+: 330.07.
4-Acetyl-1-(4-chlorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihy-
dro-2H-pyrrol-2-one (30).32 Started from cyclohexane carboxalde-
hyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 4-chloroaniline 2e (544
mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554
μL, 4.42 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 713 mg, 48%,
light-yellow solid. 1H NMR (400 MHz, CDCl3): δ 8.75 (s br, 1H),
7.42 (d, J = 8.8 Hz, 2H), 7.39 (d, J = 9.2 Hz, 2H), 4.95 (d, J = 2.0 Hz,
1H), 2.53 (s, 3H), 1.96−1.84 (m, 1H), 1.75−1.65 (m, 1H), 1.63−
1.51 (m, 3H), 1.45−1.40 (m, 1H), 1.11−0.97 (m, 3H), 0.95−0.86
(m, 1H), 0.66 (qd, J = 12.4, 3.2 Hz, 1H) ppm. MS [ESI + H]+: 334.1.
4-Acetyl-1-(4-bromophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihy-
dro-2H-pyrrol-2-one (31).32 Started from cyclohexane carboxalde-
hyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 4-bromoaniline 2f (760
mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554
μL, 4.42 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 910 mg, 53%,
white solid. 1H NMR (400 MHz, CDCl3): δ 7.57 (d, J = 8.4 Hz, 2H),
7.33 (d, J = 8.4 Hz, 2H), 4.96 (s, 1H), 2.53 (s, 3H), 1.97−1.87 (m,
1H), 1.73−1.65 (m, 1H), 1.62−1.49 (m, 3H), 1.45−1.37 (m, 1H),
1.15−0.97 (m, H), 0.95−0.86 (m, 1H), 0.66 (qd, J = 12.4, 3.2 Hz,
1H) ppm. MS [ESI + H]+: 378.1.
4-Acetyl-5-cyclohexyl-3-hydroxy-1-(4-(triﬂuoromethyl)phenyl)-
1,5-dihydro-2H-pyrrol-2-one (32).32 Started from cyclohexane
carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 4-triﬂuor-
omethylaniline 2g (556 μL, 4.42 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of
AcOH. Yield: 80 mg, 5%, white solid. 1H NMR (400 MHz, DMSO-
d6) δ 12.25 (s, 1H), 7.82 (s, 4H), 5.19 (s, 1H), 2.46 (s, 3H), 1.85 (t, J
= 11.2 Hz, 1H), 1.60 (d, J = 10.8 Hz, 1H), 1.54−1.43 (m, 3H), 1.38
(d, J = 12.4 Hz, 1H), 1.05−0.74 (m, 4H), 0.52 (d, J = 12.4 Hz, 1H)
ppm. MS [ESI + H]+: 369.07.
4-Acetyl-5-cyclohexyl-3-hydroxy-1-(3-methylphenyl)-1,5-dihy-
dro-2H-pyrrol-2-one (33).29 Started from cyclohexane carboxalde-
hyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 3-methylaniline 2h (474
μL, 4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554
μL, 4.42 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 511 mg, 37%,
white solid. 1H NMR (400 MHz, CDCl3): δ 7.32 (t, J = 8.0 Hz, 1H),
7.26 (s, 1H), 7.19 (d, J = 8.0 Hz, 1H), 7.11 (d, J = 7.6 Hz, 1H), 4.96
(d, J = 2.0 Hz, 1H), 2.53 (s, 3H), 2.40 (s, 3H), 1.95−1.88 (m, 1H),
1.69−1.65 (m, 1H), 1.59−1.50 (m, 3H), 1.45−1.39 (m,1H), 1.15−
0.84 (m, 4H), 0.64 (qd, J = 12.4, 3.6 Hz, 1H) ppm. MS [ESI + H]+:
314.07.
4-Acetyl-5-cyclohexyl-1-(3-ﬂuorophenyl)-3-hydroxy-1,5-dihydro-
2H-pyrrol-2-one (34).32 Started from cyclohexane carboxaldehyde 1a
(534 μL, 4.42 mmol, 1.00 equiv), 3-ﬂuoroaniline 2i (425 μL, 4.42
mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL, 4.42
mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 226 mg, 16%, white
solid. 1H NMR (400 MHz, CDCl3): δ 8.99 (s br, 1H), 7.45−7.34 (m,
1H), 7.29−7.25 (m, 1H), 7.21 (d, J = 8.0 Hz, 1H), 7.01 (td, J = 8.0,
2.0 Hz, 1H), 4.97 (d, J = 2.0 Hz, 1H), 2.55 (s, 3H), 1.94 (td, J = 12.0,
2.0 Hz, 1H), 1.70−1.67 (m, 1H), 1.62−1.53 (m, 3H), 1.47−1.40 (m,
1H), 1.15−0.97 (m, 3H), 0.96−0.84 (m, 1H), 0.66 (qd, J = 12.4, 3.6
Hz, 1H) ppm. MS [ESI + H]+: 318.27.
4-Acetyl-1-(3-chlorophenyl)-5-cyclohexyl-3-hydroxy-1,5-dihy-
dro-2H-pyrrol-2-one (35).29 Started from cyclohexane carboxalde-
hyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 3-chloroaniline 2j (468 μL,
4.42 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a (554 μL,
4.42 mmol, 1.00 equiv) in 10 mL of AcOH. Yield: 805 mg, 55%,
yellow solid. 1H NMR (400 MHz, CDCl3): δ 8.92 (s br, 1H), 7.51 (t,
J = 1.6 Hz, 1H), 7.38 (t, J = 8.0 Hz, 1H), 7.32 (d, J = 8.0 Hz, 1H),
7.29−7.25 (m, 1H), 4.96 (d, J = 2.0 Hz, 1H), 2.55 (s, 3H), 1.93 (td, J
= 12.4, 2.0 Hz, 1H), 1.71−1.68 (m, 1H), 1.60−1.54 (m, 3H), 1.46−
1.43 (m, 1H), 1.15−0.99 (m, 3H), 0.98−0.86 (m, 1H), 0.65 (qd, J =
12.4, 2.8 Hz, 1H) ppm. MS [ESI + H]+: 334.13.
4-Acetyl-5-cyclohexyl-3-hydroxy-1-(3-(triﬂuoromethyl)phenyl)-
1,5-dihydro-2H-pyrrol-2-one (36). Started from cyclohexane carbox-
aldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 3-triﬂuoromethylani-
line 2k (552 μL, 4.42 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of
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AcOH. Yield: 560 mg, 34%, brown solid. 1H NMR (400 MHz,
DMSO-d6): δ 12.26 (br s, 1H), 7.98 (s, 1H), 7.86 (d, J = 7.6 Hz, 1H),
7.69 (t, J = 8.0 Hz, 1H), 7.64 (d, J = 7.6 Hz, 1H), 5.23 (d, J = 1.2 Hz,
1H), 2.45 (s, 3H), 1.86 (t, J = 11.2 Hz, 1H), 1.62−1.58 (m, 1H),
1.47−1.35 (m, 4H), 1.00−0.85 (m, 3H), 0.80−0.71 (m, 1H), 0.47
(qd, J = 12.8 Hz, 3.2 Hz, 1H) ppm. MS [ESI + H]+: 368.13.
4-Acetyl-5-cyclohexyl-1-(2-ﬂuoro-4-methylphenyl)-3-hydroxy-
1,5-dihydro-2H-pyrrol-2-one (37).29 Started from cyclohexane
carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 2-ﬂuoro-4-
methylaniline 2l (499 μL, 4.42 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of
AcOH. Yield: 508 mg, 35%, white solid. 1H NMR (400 MHz,
CDCl3): δ 9.35 (br s, 1H), 7.28−7.22 (m, 1H), 7.04−6.98 (m, 2H),
4.93 (d, J = 1.6 Hz, 1H), 2.52 (s, 3H), 2.39 (s, 3H), 1.98−1.91 (m,
1H), 1.69−1.63 (m, 1H), 1.57−1.41 (m, 4H), 1.13−1.02 (m, 3H),
0.92−0.82 (m, 1H), 0.62 (qd, J = 12.8 Hz, 3.2 Hz, 1H) ppm. MS [ESI
+ H]+: 332.1.
4-Acetyl-1-(4-chloro-2-ﬂuorophenyl)-5-cyclohexyl-3-hydroxy-
1,5-dihydro-2H-pyrrol-2-one (38).29 Started from cyclohexane
carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 4-chloro-2-
ﬂuoroaniline 2m (490 μL, 4.42 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of
AcOH. Yield: 190 mg, 12%, light-yellow solid. 1H NMR (400 MHz,
CDCl3): δ 9.07 (br s, 1H), 7.37 (t, J = 8.4 Hz, 1H), 7.28−7.22 (m,
2H), 4.96 (d, J = 2.0 Hz, 1H), 2.52 (s, 3H), 2.00−1.91 (m, 1H),
1.72−1.65 (m, 1H), 1.63−1.44 (m, 4H), 1.14−1.00 (m, 2H), 0.99−
0.82 (m, 2H), 0.61 (qd, J = 12.8 Hz, 3.6 Hz, 1H) ppm. MS [ESI +
H]+: 352.1.
4-Acetyl-1-(4-bromo-2-ﬂuorophenyl)-5-cyclohexyl-3-hydroxy-
1,5-dihydro-2H-pyrrol-2-one (39).32 Started from cyclohexane
carboxaldehyde 1a (303 μL, 2.50 mmol, 1.00 equiv), 4-bromo-2-
ﬂuoroaniline 2n (475 μL, 2.50 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (395 μL, 2.50 mmol, 1.00 equiv) in 5 mL of
AcOH. Puriﬁed by silica column chromatography using EtOAc/
petroleum ether (1/6). The resulting impure product was stirred in
diisopropylether, and the pure product was obtained by ﬁltration.
Yield: 36 mg, 4%, white solid. 1H NMR (400 MHz, CDCl3): δ 8.97 (s
br, 1H, OH), 7.43−7.36 (m, 2H), 7.31 (t, J = 8.0 Hz, 1H), 4.96 (d, J
= 1.2 Hz, 1H), 2.52 (s, 3H), 1.94 (t, J = 11.6 Hz, 1H), 1.68 (d, J =
13.2 Hz, 1H), 1.57−1.42 (m, 4H), 1.15−0.84 (m, 4H), 0.62 (qd, J =
12.4, 3.2 Hz, 1H) ppm. MS [ESI + H]+: 395.67.
4-Acetyl-5-cyclohexyl-1-(3,4-dimethylphenyl)-3-hydroxy-1,5-di-
hydro-2H-pyrrol-2-one (40).32 Started from cyclohexane carboxalde-
hyde 1a (303 μL, 2.50 mmol, 1.00 equiv), 3,4-dimethylaniline 2o
(303 μL, 2.50 mmol, 1.00 equiv), and ethyl 2,4-dioxopentanoate 3a
(395 μL, 2.50 mmol, 1.00 equiv) in 5 mL of AcOH. Yield: 167 mg,
20%, white solid. 1H NMR (400 MHz, CDCl3): δ 9.06 (s br, 1H,
OH), 7.21−7.16 (m, 2H), 7.10 (dd, J = 8.0, 1.6 Hz, 1H), 4.92 (d, J =
2.0 Hz, 1H), 2.53 (s, 3H), 2.29 (s, 3H), 2.28 (s, 3H),1.92 (t, J = 11.6
Hz, 1H), 1.73−1.65 (m, 1H), 1.60−1.49 (m, 3H), 1.42 (d, J = 12.4
Hz, 1H), 1.13−0.98 (m, 3H), 0.94−0.84 (m, 1H), 0.65 (qd, J = 12.0,
3.2 Hz, 1H) ppm. MS [ESI + H]+: 327.87.
4-Acetyl-1-(4-chloro-3-methylphenyl)-5-cyclohexyl-3-hydroxy-
1,5-dihydro-2H-pyrrol-2-one (41).29 Started from cyclohexane
carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 4-chloro-3-
methylaniline 2p (626 mg, 4.42 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of
AcOH. Yield: 505 mg, 33%, white solid. 1H NMR (400 MHz,
CDCl3): δ 9.39 (s br, 1H, OH), 7.40 (d, J = 8.4 Hz, 1H), 7.32 (d, J =
2.0 Hz, 1H), 7.17 (dd, J = 8.4, 2.4 Hz, 1H), 4.94 (d, J = 2.0 Hz, 1H),
2.55 (s, 3H), 2.42 (s, 3H), 1.93 (td, J = 12.0, 2.4 Hz, 1H), 1.72−1.64
(m, 1H), 1.60−1.49 (m, 3H), 1.46−1.34 (m,1H), 1.15−0.96 (m,
3H), 0.94−0.84 (m, 1H), 0.65 (qd, J = 12.8, 3.6 Hz, 1H) ppm. MS
[ESI + H]+: 348.0.
4-Acetyl-5-cyclohexyl-1-(3-ﬂuoro-4-methylphenyl)-3-hydroxy-
1,5-dihydro-2H-pyrrol-2-one (42).32 Started from cyclohexane
carboxaldehyde 1a (534 μL, 4.42 mmol, 1.00 equiv), 3-ﬂuoro-4-
methylaniline 2q (506 μL, 4.42 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (554 μL, 4.42 mmol, 1.00 equiv) in 10 mL of
AcOH. Yield: 160 mg, 10%, white solid. 1H NMR (400 MHz, CDCl3)
δ 7.24 (t, J = 8.0 Hz, 1H), 7.18 (dd, J = 6.8, 2.0 Hz, 1H), 7.09 (dd, J =
8.4, 2.0 Hz, 1H), 4.92 (d, J = 2.0 Hz, 1H), 2.54 (s, 3H), 2.30 (d, J =
1.6 Hz, 3H), 1.94 (td, J = 12.0, 2.0 Hz, 1H), 1.74−1.64 (m, 1H),
1.64−1.48 (m, 3H), 1.48−1.39 (m, 1H), 1.14−0.98 (m, 3H), 0.98−
0.84 (m, 1H), 0.67 (qd, J = 12.8, 3.2 Hz, 1H). MS [ESI + H]+:
332.00.
1-(4-Bromo-2-ﬂuorophenyl)-5-cyclohexyl-4-(cyclopropanecar-
bonyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one (43). Started from
cyclohexane carboxaldehyde 1a (242 μL, 2.00 mmol, 1.00 equiv), 4-
bromo-2-ﬂuoroaniline 2n (380 mg, 2.00 mmol, 1.00 equiv), and ethyl
4-cyclopropyl-2,4-dioxobutanoate51 3f (368 mg, 2.00 mmol, 1.00
equiv) in 5 mL of AcOH. Yield: 240 mg, 28%, white solid. 1H NMR
(400 MHz, CDCl3): δ 7.43−7.34 (m, 3H), 5.06 (d, J = 1.6 Hz, 1H),
2.39−2.33 (m, 1H), 1.92 (t, J = 12.0 Hz, 1H), 1.72 (d, J = 12.4 Hz,
1H), 1.64−1.48 (m, 4H), 1.35−1.31 (m, 1H), 1.25−1.22 (m, 1H),
1.13−1.01 (m, 5H), 0.99−0.90 (m, 1H), 0.68 (qd, J = 12.4, 3.2 Hz,
1H) ppm. MS [ESI + H]+: 421.67.
4-Benzoyl-1-(4-bromo-2-ﬂuorophenyl)-5-cyclohexyl-3-hydroxy-
1,5-dihydro-2H-pyrrol-2-one (44). Started from cyclohexane carbox-
aldehyde 1a (242 μL, 2.00 mmol, 1.00 equiv), 4-bromo-2-ﬂuoroani-
line 2n (380 mg, 2.00 mmol, 1.00 equiv), and ethyl 2,4-dioxo-4-
phenylbutanoate53 3i (440 mg, 2.00 mmol, 1.00 equiv) in 5 mL of
AcOH. Yield: 210 mg, 23%, white solid. 1H NMR (400 MHz,
DMSO): δ 7.84 (d, J = 6.8 Hz, 2H), 7.78 (dd, J = 10.4, 2.0 Hz, 1H),
7.67−7.60 (m, 2H), 7.58−7.51 (m, 3H), 5.21 (d, J = 2.0 Hz, 1H),
1.64−1.44 (m, 6H), 1.00−0.70 (m, 5H) ppm. MS [ESI + H]+:
459.87.
1-(4-Bromo-2-ﬂuorophenyl)-5-(3-bromophenyl)-4-(cyclopropa-
necarbonyl)-3-hydroxy-1,5-dihydro-2H-pyrrol-2-one (45). Started
from 3-bromobenzaldehyde 1l (233 μL, 2.00 mmol, 1.00 equiv), 4-
bromo-2-ﬂuoroaniline 2n (380 mg, 2.00 mmol, 1.00 equiv), and ethyl
4-cyclopropyl-2,4-dioxobutanoate51 3f (440 mg, 2.00 mmol, 1.00
equiv) in 5 mL of AcOH. Yield: 205 mg, 21%, oﬀ-white solid. 1H
NMR (400 MHz, CDCl3): δ 7.40 (d, J = 6.8 Hz, 1H), 7.35−7.27 (m,
2H), 7.22 (d, J = 8.4 Hz, 1H), 7.19−7.11 (m, 2H), 7.07 (t, J = 8.0 Hz,
1H), 5.84 (s, 1H), 1.93−1.85 (m, 1H), 1.22−1.19 (m, 1H), 1.07−
0.97 (m, 2H), 0.82−0.74 (m, 1H) ppm. MS [ESI + H]+: 495.67.
4-Acetyl-1-(4-bromo-2-ﬂuorophenyl)-5-(3-bromophenyl)-3-hy-
droxy-1,5-dihydro-2H-pyrrol-2-one (46). Started from 3-bromoben-
zaldehyde 1l (291 μL, 2.50 mmol, 1.00 equiv), 4-bromo-2-
ﬂuoroaniline 2n (475 mg, 2.50 mmol, 1.00 equiv), and ethyl 2,4-
dioxopentanoate 3a (395 mg, 2.50 mmol, 1.00 equiv) in 5 mL of
AcOH. Puriﬁed by silica column chromatography using EtOAc/
petroleum ether (1/19). Yield: 82 mg, 5%, yellow solid. 1H NMR
(400 MHz, CDCl3): δ 7.41 (dt, J = 7.6, 1.6 Hz, 1H), 7.33−7.24 (m,
2H), 7.22 (d, J = 8.4 Hz, 1H), 7.19−7.11 (m, 2H), 7.08 (t, J = 8.0 Hz,
1H), 5.74 (s, 1H), 2.17 (s, 3H) ppm. MS [ESI + H]+: 469.60.
In Vitro Characterization of Compound’s Activity. Chemicals
and Reagents. [3H]-CCR2-RA-[R] (speciﬁc activity 59.6 Ci
mmol−1), corresponding to the (R)-isomer of compound 38 ([3H]-
(R)-4-acetyl-1-(4-chloro-2-ﬂuorophenyl)-5-cyclohexyl-3-hydroxy-1,5-
dihydro-2H-pyrrol-2-one)), was custom-labeled by Vitrax (Placentia,
CA). [35S]GTPγS (guanosine 5′-O-(3-[35S]thio)triphosphate), with a
speciﬁc activity of 1250 Ci mmol−1, was purchased from PerkinElmer
(Waltham, MA). CCR2-RA-[R], SD-24, and JNJ-27141491 were
synthesized as described previously.30,36,54 BX471 was purchased from
Cayman Chemical (Ann Arbor, MI, USA). Chemokine ligands CCL2
and CCL3 were purchased from PeproTech (Rocky Hill, NJ). Bovine
serum albumin (BSA, fraction V) was purchased from Sigma (St.
Louis, MO, USA). Bicinchoninic acid (BCA) and BCA protein assay
reagent were purchased from Pierce Chemical Company (Rockford,
IL, USA). Tango CCR1-bla and Tango CCR2-bla osteosarcoma
(U2OS) cells stably expressing the human CCR1 or human CCR2b
(U2OS-CCR1 or U2OS-CCR2, respectively) were obtained from
Invitrogen (Carlsbad, CA). All other chemicals were obtained from
standard commercial sources.
Cell Culture and Membrane Preparation. U2OS-CCR1 and
U2OS-CCR2 were grown in a humidiﬁed atmosphere at 37 °C and
5% CO2 in McCoy’s 5A medium supplemented with 10% fetal calf
serum, 2 mM glutamine, 0.1 mM nonessential amino acids (NEAAs),
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25 mM HEPES, 1 mM sodium pyruvate, 100 IU/ml penicillin, 100
μg/mL streptomycin, 100 μg/mL G418, 50 μg/mL hygromycin, and
125 μg/mL zeocin (200 μg/mL zeocin for U2OS-CCR1). Cells were
subcultured twice a week at a ratio of 1:3 to 1:8 on 10 cm Ø plates by
trypsinization. For membrane preparation cells were subcultured on
15 cm Ø plates using dialyzed fetal calf serum. Membranes from
U2OS-CCR1 and U2OS-CCR2 cells were prepared as described
previously.26 Brieﬂy, cells were detached from conﬂuent 15 cm Ø
plates by scraping them into 5 mL of phosphate-buﬀered saline
(PBS), collected, and centrifuged for 5 min at 3000 rpm (700g). The
pellets were resuspended in ice-cold 50 mM Tris-HCl buﬀer, pH 7.4,
supplemented with 5 mM MgCl2, and homogenized with an Ultra
Turrax homogenizer (IKA-Werke GmbH & Co. KG, Staufen,
Germany). Membranes were separated from the cytosolic fraction
by several centrifugation steps in an Optima LE-80 K ultracentrifuge
(Beckman Coulter, Inc., Fullerton, CA) at 31000 rpm for 20 min at 4
°C. Finally, the membrane pellets were resuspended in 50 mM Tris-
HCl buﬀer supplemented with 5 mM MgCl2, pH 7.4, divided into
aliquots of 100 μL and 250 μL, and stored at −80 °C. Membrane
protein concentrations were measured using a BCA protein
determination with BSA as a standard.55
[3H]-CCR2-RA-[R] Binding Assays. [3H]-CCR2-RA-[R] (homolo-
gous) displacement assays in U2OS-CCR1 and U2OS-CCR2 were
performed in a 100 μL reaction volume containing assay buﬀer (50
mM Tris-HCl, 5 mM MgCl2, and 0.1% CHAPS, pH 7.4), 6 nM [
3H]-
CCR2-RA-[R], 8−15 μg of membrane protein, and the competing
ligand. Homologous displacement assays were carried out with three
diﬀerent concentrations of [3H]-CCR2-RA-[R], namely 3, 6, and 12
nM. In all cases, at least six concentrations of competing ligand were
used and the reaction mixture was incubated for 120 min at 25 °C.
Nonspeciﬁc binding was determined in the presence of 10 μM CCR2-
RA-[R]. Total radioligand binding did not exceed 10% of the amount
added to prevent ligand depletion. [3H]-CCR2-RA-[R] saturation
binding assays in U2OS-CCR2 were also performed in a 100 μL
reaction volume containing assay buﬀer, [3H]-CCR2-RA-[R] in 12
diﬀerent concentrations ranging from 0.05 to 70 nM, and 15 μg of
membrane protein. Nonspeciﬁc binding was determined in the
presence of 10 μM JNJ-27141491 at four diﬀerent concentrations of
radioligand, namely 0.1, 0.4, 2.5, and 20 nM. In association assays,
U2OS-CCR1 and U2OS-CCR2 membrane preparations were added
to the reaction mix at diﬀerent time points of incubation, ranging
from 1 to 180 min incubation; in dissociation assays, membranes were
ﬁrst incubated with 6 nM [3H]-CCR2-RA-[R] for 90 min, and
dissociation was initiated by the addition of 10 μM CCR2-RA-[R] at
diﬀerent time points, up to 150 min for CCR1 and 180 min for
CCR2. For all experiments, incubations were terminated by dilution
with ice-cold wash buﬀer (50 mM Tris-HCl buﬀer supplemented with
5 mM MgCl2 and 0.05% CHAPS, pH 7.4). Separation of bound from
free radioligand was performed by rapid ﬁltration through a 96-well
GF/B ﬁlter plate using a PerkinElmer Filtermate harvester
(PerkinElmer, Groningen, The Netherlands). Filters were washed
10 times with ice-cold wash buﬀer. Then 25 μL of Microscint
scintillation cocktail (PerkinElmer, Groningen, The Netherlands) was
added to each well and the ﬁlter-bound radioactivity was determined
by scintillation spectrometry using the P-E 2450 Microbeta2
scintillation plate counter (PerkinElmer, Groningen, The Nether-
lands).
[35S]GTPγS Binding Assays. [35S]GTPγS binding assays were
performed as described previously.26 Brieﬂy, binding assays were
performed in a 100 μL reaction volume containing assay buﬀer (50
mM Tris-HCl, 5 mM MgCl2, 100 mM NaCl, 1 mM EDTA, and
0.05% BSA, pH 7.4), 10 μM GDP, 10 μg of saponin, and 10 μg of
membrane, either U2OS-CCR1 or U2OS-CCR2. To determine the
EC50 value of CCL2 and CCL3, the membrane mixture was
preincubated with increasing concentrations of chemokine for 30
min at 25 °C. To determine the IC50 values of the ligands, the
membrane mixture was preincubated with increasing concentrations
of the ligand of interest in the absence or presence of a ﬁxed
concentration of CCL2 (20 nM) or CCL3 (8 nM). Basal activity was
determined in the absence of any ligand or chemokine. Finally, the
mixture was incubated for another 90 min at 25 °C after the addition
of 0.3 nM [35S]GTPγS in all cases. For all experiments, incubations
were terminated by dilution with ice-cold 50 mM Tris-HCl, 5 mM
MgCl2 buﬀer. Separation of bound from free [
35S]GTPγS was
performed as described under “[3H]-CCR2-RA-[R] binding assays”.
Data Analysis. All experiments were analyzed using GraphPad
Prism 7.0 (GraphPad Software Inc., San Diego, CA, USA). The KD
and Bmax values of [
3H]-CCR2-RA-[R] in U2OS-CCR2 were
calculated from saturation experiments by ﬁtting the data to the
equation Bound = (Bmax*[L])/([L] + KD), where Bmax is the
maximum number of binding sites and KD is the concentration
required to reach half-maximum binding at equilibrium conditions. In
the case of U2OS-CCR1 membranes, the KD and Bmax values were
calculated from homologous binding experiments by nonlinear
regression analysis, using the “One Site−Homologous” model that
assumes that unlabeled and labeled CCR2-RA-[R] have identical
aﬃnities. The (p)IC50 values of unlabeled ligands from [
3H]-CCR2-
RA-[R] binding assays were obtained by nonlinear regression analysis
of the displacement curves and further converted into (p)Ki values
using the Cheng−Prusoﬀ equation.56 The (p)IC50 or (p)EC50 values
from [35S]GTPγS curves were also obtained by nonlinear regression.
The observed association rate constants (kobs,fast; kobs,slow) were
calculated by ﬁtting the data to a two-phase exponential association
function; similarly, dissociation rate constants (koff,fast; koff,slow) were
calculated using a two-phase exponential decay function. All values
obtained are means ± standard error of the mean (SEM) of at least
three independent experiments performed in duplicate, unless stated
otherwise. Diﬀerences in kinetic rates and pIC50 values between
receptors or between assay formats (in the absence or presence of
chemokine) were analyzed using an unpaired, two-tailed Student’s t-
test with Welch’s correction; diﬀerences in pKi values between
compounds, in maximal [35S]GTPγS inhibition against basal activity
or in pseudo-Hill slopes from [35S]GTPγS inhibition curves against
compound 45, which showed a pseudo-Hill slope of approximately
unity, were analyzed using a one-way ANOVA with Dunnett’s
posthoc test. Signiﬁcant diﬀerences are displayed as *, p < 0.05; **, p
< 0.01; ***, p < 0.001; and ****, p < 0.0001.
Computational Receptor Modeling and Docking. All modeling
was performed in the Schrodinger suite,57 Figure 3b,c were made in a
later version58 that includes the interaction and orientation of residues
(e.g., backbone, side chain). As a starting point for the structure-based
studies we used the recently published crystal structure of CCR2b in
complex with both BMS-681 and CCR2-RA-[R] (PDB 5T1A).24 We
replaced the sequence (CCR2b: sequence between L2265x62 and
R2406x32) of the M2 muscarinic acetylcholine receptor, close to the
intracellular binding site, by the CCR2b sequence using homology
modeling59−61 and CCR5 as template (PDB 4MBS).62 A homology
model of CCR1 was constructed on the basis of this CCR2b model.
For both models, the knowledge-based scoring function was used. For
the ligand docked, the pKa of the hydroxyl hydrogen was calculated to
be 4.5 using Jaguar;63,64 therefore, the negatively charged protonation
state was used. Compound CCR2-RA-[R] was docked in both models
using Induced Fit docking.65,66 Visualizations were created using
PyMOL;67 residues within 5 Å of the ligand and facing the binding
site are shown.
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